Pluristem shares spike on new batch of positive data; HGS offering $400M in senior notes;

@FierceBiotech: Upstart Verastem challenges Wall Street with puzzling $50M IPO. Article | Follow @FierceBiotech

@JohnCFierce: The S1 on Verastem is really kinda funny. The science is unproven, they're still preclinical, and they've only spent a little more than $8M. | Follow @JohnCFierce

@RyanMFierce: ImmunoGen due $1M milestone from Amgen related to $AMGN's IND for an anticancer drug that use's $IMGN's TAP tech. IMGN stock up 44.7% YTD. | Follow @RyanMFierce

@MaureenFierce: Fantastic read: With vaccines, Bill Gates changes the world a second time. Article | Follow @MaureenFierce

> Shares of Pluristem Therapeutics spiked on new positive data for its lead product, PLX-PAD for critical limb ischemia. Story

> Human Genome Sciences is planning to offer $400 million in senior notes. Item

> Chelsea Therapeutics says an interim analysis from the lower two of three doses of CH-4051 shows that patients in the mid-range, or 1.0 mg daily oral dose, arm experienced similar efficacy to patients treated with a standard 20.0 mg weekly dose of methotrexate. Release

Pharma News

@FiercePharma: Fierce's 2011 warning letters report. Report. Our picks for the top warning letters from the last 12 months. | Follow @FiercePharma

> Teva, P&G detail consumer healthcare JV. More

> Study: Chantix unsuitable for first-line use. Article

> GSK settles U.S. investigation for $3B. News

> Sanofi sees profits hit in Q3, sees strength in diabetes. Report

> Teva, generics groups answer call on drug shortages. Story

> Dendreon beaten down again on so-so Provenge sales update. Report

Vaccine News

> GSK taps Alnylam tech for faster vaccine production. Report

> Baxter recalls 300K flu vaccines. Article

> Forbes profiles Gates' emergence as vaccine powerhouse. Story

> PATH's Elias, Novartis' Mundel appointed to Gates Foundation positions. News

> Daiichi sets up vaccine R&D unit in Japan. Item

> TapImmune, Aeras team on TB vaccine. Report

Manufacturing News

> GSK, Alnylam team to speed vaccine production. Item

> HHS details manufacturing role in drug shortages. News

> FDA details its actions on shortages. Article

> China ready to take on the world. Story

> GSK, Pfizer set HIV drug manufacturing in Russia. Report

And Finally... Jonathan Wallis, associate professor of psychology and neuroscience at University of California, Berkeley has been studying the brain circuitry involved in addictive behavior in an effort to find a better way to treat it. Story

Suggested Articles

Biogen will develop a gene therapy with the goal of preserving and possibly restoring vision in patients with PRPF31-mutated retinitis pigmentosa.

A month after moving its COVID-19 antibody cocktail into human trials, Regeneron is testing the drug's ability to ward off COVID-19 infection.

Short reports are nothing new, but the aggressive “I’m coming after you” PR from Applied Therapeutics certainly is.